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ABSTRACT 
AIM: Metoclopramide is a drug that has been used in the dose of 10 mg iv for postoperative 
nausea and vomiting (PONV) prophylaxis for many years and has been reported to be ineffective 
at this dose. That a higher dose of this drug, when used in combination with 8 mg 
dexamethasone, is more effective when compared with 8 mg dexamethasone only is worth 
validating and this study was designed to do. The aim is to compare the effectiveness of adding 
50 mg metoclopramide (in two divided doses) to 8 mg intravenous dose of dexamethasone 
versus 8 mg dexamethasone only as a prophylactic anti-emetic in gynaecological surgery under 
spinal anaesthesia at University of Ilorin Teaching Hospital, Ilorin. 
MATERIAL AND METHOD: This was a prospective, controlled study in which seventy-four 
ASA physical status 1 and 2 eligible gynaecological patients with 37 patients per group, were 
randomly allocated to either the metoclopramide and dexamethasone group or the 
dexamethasone only group for the purpose of this study. A simple random technique of balloting 
was used for randomization of the study population. Every participant was preloaded with one 
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litre of normal saline. Spinal Anaesthesia was established with 3 ml of 0.5 percent hyperbaric 
bupivacaine and 25 µg of fentanyl.  Both groups received 8 mg dexamethasone iv immediately 
after induction of spinal anaesthesia. The test group received 25 mg of metoclopramide iv after 
establishment of spinal anaesthesia and another dose of 25 mg metoclopramide iv at the end of 
surgery while the control group received normal saline at both times respectively. Data on 
PONV were collated for 24 hours postoperatively using a study pro-forma. Vital signs such as 
pulse, SaO2 and BP as well as postoperative pain were monitored according to the study 
protocol.  
During the 24-hour period of the study, patients in the metoclopramide group were found to have 
a lower incidence of PONV (11% Vs 44%, p=0.003). This is statistically significant. During the 
early postoperative period (0-4 h) and late period (5-24 h), the incidence of PONV remained 
higher in the dexamethasone only group; (30.6% Vs 8.3%) and (13.9% Vs 2.8%) respectively. 
The differences between the two groups were statistically significant for 0-4 h (P = 0.02) but not 
significant for 5-24 h (P = 0.09).   
CONCLUSION: Intravenous 50 mg metoclopramide in two divided doses added to 8 mg 
dexamethasone is more effective than 8 mg dexamethasone only in reducing the incidence of 
PONV in women undergoing gynaecological surgery under spinal anaesthesia. 
{Citation:  Orewole O. T., Aremu S. K., Bolaji B. O., Kolawole I. K.  Comparative trial of 
combined metoclopramide and dexamethasone versus dexamethasone in postoperative nausea 
and vomiting in gynaecological surgery.  American Journal of Research Communication, 2014, 
2(5): 213-257}  www.usa-journals.com,  ISSN: 2325-4076.   
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INTRODUCTION 
Although, many physicians continue to view postoperative nausea and vomiting (PONV) as a 
minor complication that poses  little problem, most patients view this complication as more 
debilitating than the surgery itself.1 Patients often rate postoperative nausea and vomiting as 
worse than postoperative pain.2, 3 Prevention of postoperative nausea and vomiting has been 
found to  improve satisfaction among patients who are likely to experience them.4 This 
complication is not only unpleasant and aesthetically displeasing to patients and their care givers 
but, when severe, is associated with electrolyte imbalance, dehydration, bleeding, wound 
dehiscence  and rarely, pulmonary aspiration of gastric contents.1 
  Most gynaecological surgeries are associated with high incidence of PONV.1 In Ibadan, 
Nigeria, the incidence of post operative nausea and vomiting within twenty four hours of surgery 
was 14.6% and 19.6%, respectively with female preponderance (66% of the patients who 
vomited were females) (p < 0.05).5 At the University of Ilorin Teaching Hospital, the incidence 
of PONV in gynaecological surgery was put at 30%.6                                   
 The efficacy of antiemetics is known to be improved by combining two or three interventions.7,8 
An example of such combination is dexamethasone and metoclopramide.8 Tzeng et al compared 
low-dose dexamethasone with metoclopramide and normal saline and noticed that the total 
frequency of nausea and vomiting in the dexamethasone group was significantly lower than the 
metoclopramide and saline groups.9 
 Jan Wallenborn et al also investigated the efficacy and safety of three doses of metoclopramide 
(10 mg, 25 mg, and 50 mg) on the assumption that each patient would receive basic antiemetic 
prophylaxis of 8 mg dexamethasone.8They found that 25 mg or 50 mg metoclopramide added to 
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the basic intervention of 8 mg dexamethasone was effective, safe, and cheap. Fifty milligrams 
metoclopramide was however found to be more effective than 25 mg over 24 hours 
postoperatively. In their study the 50 mg was given as a single dose intra-operatively but 
suggested that if given in divided doses of 25 mg   intra-operatively and 25 mg immediately after 
surgery it would be as effective and may further reduce the side effect of this drug. 
 There is the need for a similar but modified study in this environment to verify this research and 
determine if indeed dividing the 50 mg metoclopramide into two equal doses will produce 
additive antiemetic effect with minimal adverse effects. This is because both metoclopramide 
and dexamethasone are relatively cheap and readily available in our environment. 
The general objective of the study was to find out if both 50 mg metoclopramide in two divided 
doses and 8 mg dexamethasone would be more effective than 8 mg dexamethasone as 
prophylactic antiemetic in patients undergoing gynaecological surgery. 
The specific objective are : 
1. To determine the efficacy of a combination of 50 mg metoclopramide (in two divided 
doses) and 8 mg dexamethasone in the prevention of PONV in patients undergoing 
gynaecological surgery. 
2. To assess the side effects of metoclopramide and dexamethasone used in the study. 
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MATERIAL AND METHOD 
STUDY AREA 
The study was conducted at the University of Ilorin Teaching Hospital, Ilorin (UITH). 
ETHICAL APPROVAL AND INFORMED CONSENT 
Ethical approval and consent for this study were obtained from the Ethical Review Committee of 
the Hospital. Approval and informed consent of every participating patient were obtained before 
recruitment of each patient was commenced. 
STUDY DESIGN 
This was a prospective, randomised, controlled study of combined 
metoclopramide+dexamethasone versus dexamethasone in the prevention of postoperative 
nausea and vomiting. 
 Each eligible patient was randomly allocated to either metoclopramide+dexamethasone or 
dexamethasone+normal saline groups (n=37 each) using a simple random technique of balloting. 
The duration of the study was between June 2009 and May 2010. 
SAMPLING TECHNIQUE 
Study sample was obtained from a consecutive series of patients slated for elective 
gynaecological surgery under spinal anaesthesia at the University of Ilorin Teaching Hospital 
(UITH). A simple random technique of balloting was used. 
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SAMPLE SIZE DETERMINATION 
In a previous study done by Kolawole, the incidence of PONV in gynaecological surgeries at 
University of Ilorin Teaching hospital (UITH) was 30%.6 
Using the Department of Anaesthesia records of surgical procedures done in a period of four 
years between January 2002 and December 2005 at UITH, the estimated population of elective 
gynaecological surgery was about 160 per annum and patients load for six months was about 80. 
Patient load for six months was used but data collection was spread over one year to give room 
for any logistics problems that might crop up during data collection. 
The target population was less than 10,000. The formula: n = Z2pq/d2  was first used to calculate 
the desired sample size (n) when the population is more than 10,000.78 
n = the desired sample size when population is greater than 10,000 
Z = the standard normal deviate, usually set at 1.96(or more simply at 2.0), which corresponds to 
95% confidence interval.  
p = the proportion in the target population estimated to have a particular characteristic (30% or 
0.30).6 
q = 1.0 – p 
d = degree of accuracy desired (0.05) 
n = (1.96)2(0.30)(0.70)/(0.05)2 
=323 
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 The sample size for this study was subsequently calculated using the formula78: 
       nf =n/1+ (n/N). 
Where: 
       nf = the desired sample size when population is less than 10,000 
       n= the desired sample size when the population is more than 10,000=323 
       N = the estimate of the population size = 80 
The sample size nf = 323/ {1+ (323/80)} = 65 
Minimum sample size of 65 patients was calculated 
Using the attrition rate of 10%, 72 patients was calculated. Seventy-four patients divided into 
two equal groups of 37 patients per group were eventually used for the study.  
STUDY POPULATION 
Seventy-four ASA physical status I and II female patients aged 18 years and above who were 
scheduled for gynaecological surgery under spinal anaesthesia participated in this study over a 
period of one year.     
EXCLUSION CRITERIA 
 Patients with ASA classification higher than 2, those who were lactating,  pregnant or who had 
history of PONV, motion sickness or had received an anti-emetic or steroids within the previous 
24 hours were excluded from this study. Others with gastrointestinal diseases, extrapyramidal 
disease, history of malignant hyperthermia, hepatic insufficiency, pheochromocytoma, 
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mechanical ileus, sickle cell disease, psychiatric illnesses and substance abuse including smoking 
as well as patients on anticancer treatment were also excluded from the study. Also excluded 
were patients who refused to participate in the study, those who refused spinal anaesthesia, 
patients with coagulopathy or other bleeding diathesis, patients with infection at the site of 
injection of intrathecal drugs, severe hypovolaemia, increased intracranial pressure, severe aortic 
stenosis, severe mitral stenosis and those with previous history of adverse reaction to 
dexamethasone, metoclopramide and bupivacaine. 
STUDY PROTOCOL 
PREOPERATIVE ASSESSMENT/ PREMEDICATION 
Consented Patients aged 18 years and above and who were scheduled for gynaecological surgery 
under spinal anaesthesia were recruited into the study during preoperative round on the ward. 
Each patient was reviewed a night before surgery by the investigator. Adequate history including 
Bio data was taken.  Previous medical history to exclude history of motion sickness, previous 
PONV and other exclusion criteria was taken and thorough physical examination was carried 
out. American Society of Anesthesiology (ASA) physical status classification was determined. 
Height and the weight were also measured and recorded. The anaesthetic procedure as well as 
benefits and possible adverse effects of the study drugs, anaesthetic drugs and that of the 
procedure were explained to the patients. Consent for spinal anaesthesia and voluntary 
participation in the study was obtained from each patient. Patients were fasted from midnight and 
10 mg of oral diazepam prescribed for premedication a night before and on the morning of 
surgery. 
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IN THE THEATRE 
 On arrival at operation suite, the patients were allowed to randomly pick a ballot paper from a 
box containing seventy four (74) ballot papers. 37 papers were labelled A for 
dexamethasone+Normal Saline (control group) and 37 were labelled B for 
dexamethasone+metoclopramide combination (metoclopramide or treatment group) in sealed 
envelopes.  All safety anaesthetic precautions were taken. Patients were connected to the 
multiparameter monitor and the following vital signs were monitored noninvasively: arterial 
oxygen saturation, blood pressure, and heart rate using the PM-800 Express patient monitor (S 
Henzen Mindray Bio-medical Electronics Co.,Ltd). Intravenous access was secured with 16G 
cannula and the drugs withdrawn appropriately. 
Study medications were prepared in a double-blind fashion in identical 5 ml syringes. A doctor 
in the Department of Anaesthesia prepared the drugs while the investigator administered the 
medications. The observer was another resident doctor who monitored the patient, measured and 
collated data on the outcome variables (nausea, vomiting, time and vital signs). 
Patients were preloaded with 1 litre of normal saline over 30 minutes after which they were put 
in a sitting position for the spinal anaesthesia. The back of each patient was cleaned with 
antiseptic lotion and spirit and then draped. The appropriate lumbar inter-space was located 
between L2 and L5 and the spinal anaesthesia was induced in each patient using 3 ml of 0.5% 
hyperbaric bupivacaine and 25 µg of fentanyl. This was done using size 26 G Quincke spinal 
needles. Both groups received 8 mg of iv dexamethasone after induction of anaesthesia. The 
treatment group then received metoclopramide 25 mg iv in a 5 ml syringe while the control 
group was given 5 ml 0.9% saline iv in identical 5 ml syringe. The level of spinal block was 
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tested for using sensation to light touch and cold temperature. The maximum level of block was 
at the 5th thoracic spinal level. 
Hypotension (defined as reduction in systolic blood pressure > 30 mmhg or diastolic blood 
pressure >15 mmhg from base line) was treated with normal saline and where necessary with iv 
ephedrine 3 mg boluses. Normal saline was used for intraoperative fluid management and whole 
blood was administered whenever blood loss was more than calculated allowable blood loss. At 
the closure of the skin, another 25 mg iv metoclopramide in 5 ml syringe  was given to the 
treatment group ( metoclopramide group) while the control group received 5 ml 0.9% saline iv.  
Patients breathed spontaneously room air supplemented with 100% oxygen by facemask 
whenever SaO2 was < 95%. Patients pulse rate, blood pressure and arterial oxygen saturation 
were monitored intraoperatively every 5 minutes using the PM-800 Express patient monitor (S 
Henzen Mindray Biomedical Electronics Co., Ltd). At the end of surgery patients were 
transferred to the recovery room where monitoring of patients continued for 1 hr. Patients were 
then transferred to the ward for further observation. Morphine 5 mg iv 4 hourly, diclofenac 75 
mg im daily and paracetamol 600 mg  6 hourly iv were employed for postoperative pain 
management. Rescue anti-emetic ondansetron 4 mg iv bolus was recommended for patients who 
vomited once or more. 
Pain was assessed using the verbal rating scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 
= severe pain, 4 = excruciating pain) at 15 minute intervals during patients stay in the recovery 
room and at 4 hour, 12 hour, 16 hour and 24 hour in the ward by direct questioning by a trained 
observer (another resident doctor) blinded to the study. Breakthrough pain was controlled with 
additional doses of morphine titrated at 2 mg iv as required. The total amount of morphine 
administered to each patient was recorded. Nausea and vomiting were assessed immediately after 
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surgery and at 30-min intervals in the recovery room for 1 hour. In addition, nausea and vomiting 
were evaluated at 4 hour, 12 hour, 16 hour and 24 hour by direct questioning and by spontaneous 
complaint of the patients. Nausea and vomiting were evaluated on a 3-point ordinal scale (0 = 
none, 1 = nausea, and 2 = vomiting). No distinction was made between vomiting and retching 
(i.e., a retching event was considered as a vomiting event).  
The primary end point was a total effective antiemetic response (i.e., complete response), defined 
as no PONV and no administration of rescue antiemetic medication for 24 hour postoperatively. 
Secondary end points included the proportion of patients who experienced an episode of nausea, 
retching or vomiting, and the number of patients who needed antiemetic rescue. The details of 
adverse effects throughout the study (0-24 hour after anaesthesia) were assessed each time 
PONV was assessed. 
A simplified risk score was calculated preoperatively for each patient.40,75 This predictive score 
of PONV considers four predictors: female sex, history of PONV or motion sickness, non-
smoking and expected use of opioids; patients were assigned one point each for the risk factors. 
In a cross-validation study, patients with a risk factor of 0 had a 10% risk for PONV, those with 
a score of 1 had a risk of 21%; of 2, 39%, of 3, 61% and of 4, 79%40. All the patients used in this 
study were female, non smoker and were expected to use opioids. With the presence of 3 risk 
factors, the calculated risk for PONV was 61%. 
SPECIAL DEFINITIONS 
For the purpose of this study, and to ensure uniformity and standardization, duration of 
anaesthesia was defined as the period between intrathecal injection of hyperbaric bupivacaine 
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and the time when the patient could feel pain at the surgical site. The duration of surgery was 
taken as the period between skin incision and end of skin closure. 
DATA COLLECTION 
Nausea and vomiting and pain were assessed for 24 hrs starting from immediate postoperative 
period, in the recovery room and in the ward. 
Nausea and vomiting were evaluated on a 3 point ordinal scale (0-none; 1-nausea; 2-vomiting 
and/or retching. No nausea, no vomiting and no anti-emetic medication in the first 24-hour post-
operative period was defined as a successful end-point. 
Pain intensity was assessed using verbal rating scale. An ordinal scale of 0-4 (0- no pain, 1- mild 
pain, 2- moderate pain, 3- severe pain and 4- excruciating pain) was used.  
STATISTICAL ANALYSIS 
Data entry was done using the statistical package for the social sciences (SPSS 15.0 for windows 
evaluation version. SPSS Inc.).Two-sample independent student’s t-test (2-tailed) were used to 
analyse continuous patients’ variables like age, weight, duration of anaesthesia/surgery, 
including their mean + SD (Standard Deviation). However, chi-squared test or Fisher’s Exact test 
were used appropriately for discreet variables like symptoms of PONV (nausea, vomiting).  A p-
value of less than 0.05 was considered significant.  
Seventy four patients (37 patients each in study and control groups) were recruited into the study. 
However, two of them were disqualified because their spinal anaesthesia wore off and 
anaesthesia was converted to general anaesthesia. Data obtained from seventy-two patients were 
analysed. 
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From the analytic statistics of the patients’ characteristics (Table 1) it is apparent that patients in 
both groups had comparable demographic and clinical profiles. 
 
Table 1. Patient Demographics 
                        Metoclopramide Group                Control Group                 P- Values     
Age (yr)                             44 ± 9                                    41 ± 10                         0.124      
Weight (kg)                      70 ± 17                                  64 ± 15                         0.108 
Height (cm)                      163 ± 6                                  159 ± 5                         0.026 
BMI (kg/m2)                     27 ± 6                                     25 ± 6                           0.357 
PCV (%)                             35 ± 4                                     36 ± 4                           0.978 
Parity                                 3 ± 2                                       3 ± 2                             0.529 
ASA Score*                       1                                              1                                   0.605 
DOA  (min)                      158 ± 20                                162 ± 37                       0.507 
DOS  (min)                       129 ± 23                                130 ± 40                       0.855      
 Morphine* (mg)            39 ± 5                                     40 ± 4                           0.518 
n = 36 in each group. 
Morphine* = 24 hr morphine consumption 
Values are mean ± SD in each group.   
ASA score*- Mode values used      
 Two-sample independent student t-test confirms that continuous quantitative variables such as 
weight (P = 0.108), body mass index (BMI) (P = 0.357), duration of anaesthesia (P = 0.507), 
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duration of surgery (P = 0.855) and total morphine consumption in 24 hours (P = 0.518) were not 
statistically different between the two groups. 
                                             
RESULTS 
MAIN FINDINGS 
During the first 24 h after anaesthesia, the percentage of patients with complete response was 
88.9% in the Metoclopramide Group (Dexamethasone+Metoclopramide) and 55.6% in the 
Control Group (Dexamethasone+Normal Saline) (P = 0.002).Table 2 shows the types of 
operation done for the patients. 
Table 2. Types of Operation 
Types of operation           Metoclopramide Group n (%)            Control Group  n (%) 
Abdominal hysterectomy                      20 (55.6)                                      16 (44.4) 
Vaginal hysterectomy                           3 (8.3)                                          1 (2.8) 
Myomectomy                                        11(30.6)                                       12 (33.3) 
VVF* repair                                            0 (0)                                            1 (2.8) 
Ovarian cystectomy                               1 (2.8)                                         3 (8.3) 
Tuboplasty                                             1 (2.8)                                         2 (5.5) 
Manchester repair                                  0 (0)                                            1 (2.8) 
n = 36 in each group. 
P = 0.633             
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The incidence of nausea, vomiting and the number of patients rescued in each group is also 
shown in Table 3. 
Table 3. Patients Having Complete Response, Nausea, Vomiting, or Rescue Antiemetic 
Medication During The First 24 Hours After Anaesthesia 
                             Metoclopramide Group n (%)      Control Group n (%)       P-Values 
Complete response              32 (88.9)                               20 (55.6)               0.002 
Nausea+Vomiting                 4 (11.1)                                16 (44.4)                0.003                                                                                  
       Nausea                          4 (11.1)                                 16 (44.4)               0.003                              
       Vomiting                         0 (0)                                      4 (11.1)                 0.57      
   Multiple Nausea                 0 (0)                                      11 (30.6)               0.003 
   Multiple Vomiting                0 (0)                                      1 (2.8)                  0.218                         
Rescue                                  1 (2.8)                                   5 (13.9)                0.199                                          
 n = 36 in each group. 
 
The incidence of PONV (nausea and/or vomiting) in the Metoclopramide Group was 4 (11.1%) 
while it was 16 (44.4%) in the Control Group (P = 0.003). Similarly, 4 patients (11.1%) in the 
Metoclopramide Group had nausea while 16 patients (44.4%) in the Control Group had nausea 
(P = 0.003). No patient (0%) vomited in the Metoclopramide Group while 4 patients (11.1%) 
vomited in the Control Group (P = 0.57). This result showed that nausea was the more common 
feature of PONV than vomiting in both groups in the first 24 hour. 
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Figures1 graphically illustrates the intra-group differences in outcomes during the total study 
period (0-24 hour). Patients with complete response and less incidence of PONV are in clear 
majority in the Metoclopramide Group.  
 
 
 
 
0
10
20
30
40
50
60
70
80
90
1
No PONV 32(88.9%) 
Vomiting 0(0%) 
Nausea 4(11.1%) 
No PONV 20(55.6%) 
Vomiting 4(11.1%) 
Nausea16(44.4%) 
P
e
r
c
e
n
t
a
g
e
 
I
n
c
i
d
e
n
c
e
 
Study group 
FIGURE 1: Bar chart showing incidence of Nausea and Vomiting during the Post-
operative period of 24 hours 
No PONV
vomiting
Nausea
No PONV
vomiting
Nausea
metoclopramide +dexa 
 
dexamethasone only methasone 
American Journal of Research Communication                                    www.usa-journals.com 
Orewole, et al., 2014:  Vol 2(5)                         229                              ajrc.journal@gmail.com 
 
The incidence of vomiting was lower in the Metoclopramide Group than the Control Group for 
the same period of 0-24 h (0% Vs 11.11%). This was however not statistically significant (P = 
0.57). 
During the early postoperative period (0-4 h) and late period (5-24 h) (Table 4 and Figures 2 and 
3), the incidence of PONV continued to be  higher in the Control Group than the 
Metoclopramide Group i.e. 30.6% Vs 8.3% and 13.9% Vs 2.8% respectively. The difference was 
statistically significant for the period 0-4 hour (P = 0.02) while not significant for the period 5-24 
hour (P = 0.09). It is also noted that incidence of early PONV is higher than late PONV in both 
groups.  
Table 4. Incidence of Early and Late Postoperative Nausea and Vomiting 
                           Metoclopramide Group n (%)      Control Group n (%)        P- values 
Early PONV (0-4 hr)                        
        Complete response             33 (91.7)                5 (69.4)          
         PONV                                 3 (8.3)                    11(30.6)                   0.02          
Late PONV (5-24 hr)                                                                                          
         Complete response            35 (97.2)                31 (86.1)                     
          PONV                                1 (2.8)                     5 (13.9)                    0.09 
n = 36 in each group.             
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0.003). One patient (2.8%) in the Control Group also had multiple episodes of vomiting whereas 
no patient (0%) in the Metoclopramide Group had multiple episodes of vomiting (P = 0.218) 
(Table 3). 
The number of patients that required rescue antiemetic in the Metoclopramide Group was 1 
(2.8%) while 5 patients (13.9%) required it in the Control Group. This was however not 
statistically significant (P = 0.199). All the patients that required rescue antiemetic responded 
favourably to one dose of the antiemetic used (4 mg ondansetron iv bolus). 
 OTHER FINDINGS      
Table 5 shows the relationship between PONV and Age as well as that between PONV and 
Obesity. The patients were categorized into those with age < 50 yr and age ≥ 50 yr. The number 
of patients that were less than 50 yr was 51 while 21 patients were ≥ 50yr. The incidence of 
PONV in age < 50 yr was 28% while the incidence in ≥ 50 yr category was 29%. This was not 
statistically significant (P = 0.66). 
 Patients were also categorized into two groups based on the body mass index. There were 53 
patients with BMI < 30 and 19 patients with BMI ≥ 30. The incidence of PONV among obese 
patients (BMI ≥ 30) was 15.8% while it was 20.8% among non obese patients. This was however 
not statistically significant (P = 0.87). 
 Table 6 shows the incidence of pain in the two groups. The incidence of pain in the 
Metoclopramide Group was 33.3% and 55.6% in the Control Group. The difference was not 
statistically significant (P = 0.96). 
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Table 6. Incidence of Pain in Study Groups 
                            Metoclopramide Group n (%)           Control Group n (%)                                 
Pain                                12 (33.3%)                                     20 (55.6%)                               
No Pain                          24 (66.7%)                                     16 (44.4%)                                   
n = 36 in each group 
P = 0.96             
 
 Table 7 shows relationship between PONV and Pain. Among patients who were free of pain in 
the period 0-24 hour, 20% had PONV while 80% had no PONV. The difference was also not 
statistically significant (P = 0.099). Only one patient reported severe pain and the incidence of 
PONV in patients with severe pain was 100% (P = 0.278). This patient was in the Control 
Group. 
Table 7.  Incidence of PONV and Postoperative Pain in 24 hrs 
                                              PONV n (%)                 NO PONV n (%)             P-Values 
No Pain                                   8(20%)                         32(80%)                      0.099                         
Mild Pain                                9(36%)                         16(64%)                      0.256                      
Moderate Pain                      2(33.3%)                      4(66.7%)                     0.537  
Severe Pain                            1(100%)                       0(0%)                          0.278  
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Adverse Effects 
Table 8 shows the incidence of adverse effects in the study groups. The most frequent side 
effects were hypotension, dizziness and drowsiness which were relatively mild. No difference in 
the incidence of side effects was observed between the two groups. 
 
DISCUSSION 
Postoperative nausea and vomiting (PONV) is still the most troublesome event encountered in 
the recovery room, despite advances in prevention and treatment.79 Furthermore, the ongoing 
trend towards ambulatory procedures has increased the focus on PONV as its occurrence may 
delay discharge or cause unanticipated hospital admission.80,81 PONV is a very common 
morbidity after gynaecological procedures as reported by various studies in the past.12, 82,83 In this 
study, a highly pro-emetic setting was inadvertently provided to test the clinical efficacy of 
combination of two readily available, cheap and relatively safe anti-emetics in our environment. 
This study was designed as a prophylactic trial rather than a therapeutic one. Researchers have 
suggested restricting prophylactic trials to high risk patients and/or procedures.84 This is to 
prevent unnecessary exposures of patients to drugs and to prevent avoidable side effects and/or 
adverse reactions. Gynaecological procedures rightly belong to this category. Apfel simplified 
risk scores for the patients studied put the expected PONV risk at 61% (high risk).75 This was 
because of the presence of three risk predictors of female gender, non-smoking and use of 
postoperative opioid. The Apfel score consist of four predictors: female gender, history of 
motion sickness or PONV, non-smoking, and the use of postoperative opioids. If none, one, two, 
three, or four of these risk factors were present, the incidences of PONV were 10%, 21%, 39%, 
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61% and 79% respectively.75 Although interventions in this study were able to reduce the 
incidence of PONV in both the metoclopramide and the dexamethasone only groups to 11% and 
44% respectively from the calculated Apfel score of 61% risk, none of the two interventions 
were able to totally abolish PONV. 
 It is obvious from the obtained results that the two groups involved patients with similar and 
comparable demographic and clinical profile. Each of these characteristics has a p-value > 0.05 
(Table 1). These include number of patients in each group, age, weight, and BMI. Others are 
duration of anaesthesia/surgery and total dose of morphine administered post operatively. There 
were mild decreases in pulse rate and BP immediately after induction of spinal anaesthesia. 
These were assumed to be due to the spinal anaesthesia. Administration of normal saline was 
enough to correct the fall in BP. One patient in the dexamethasone group required the use of iv 
ephedrine 3 mg bolus to correct the hypotension. It may therefore be reasonable to say that the 
differences observed in the incidences of PONV between the two groups were due to the study 
drugs each group was exposed to, and not to any of the above variables, chance-finding or any 
other confounding variable. 
In this study, the most noticeable finding is that combination of metoclopramide and 
dexamethasone is more effective than dexamethasone alone in preventing PONV in 
gynaecological surgery whether at 0-4 hour, 5-24 hour, or 0-24 hour period of the study (Tables 
3-4 and Figures 1-3). The difference in both groups was statistically significant throughout the 
24 hour. At 0-24 hour, the incidences of PONV were 44% and 11% in the Control Group and 
Metoclopramide Group respectively (P = 0.003, Table 3). This is in agreement with previous 
findings that combination therapy is better at preventing PONV in high risk 
patients/procedures.1, 8, 70 The incidences of PONV in both groups (11% and 44% for 
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Metoclopramide Group and Control Group respectively) show that gynaecological procedures 
are highly emetogenic. 
During the early postoperative period 0-4 hour  and late period (5-24 hour)(Table 4), the 
incidence of PONV remained higher in the Control Group than the Metoclopramide Group for 
the above two periods i.e 30.6% Vs 8.3% and 13.9% Vs 2.8% respectively. The differences 
between the two groups was statistically significant for 0-4 hour (P = 0.02) but not significant for 
5-24 hour (P = 0.09).  One of the set objectives of this study was to test the hypothesis that 50 
mg metoclopramide (in two divided doses) added to 8 mg dexamethasone is effective for the 
prevention of postoperative nausea and vomiting. This study reaffirmed the hypothesis (P = 
0.002). 
Metoclopramide has been used for almost 40 years to prevent PONV.69 The affinity for 
doperminergic D2-receptors explains the antiemetic effect of metoclopramide.85 In adults, the 
most often studied regimen to prevent PONV is 10 mg metoclopramide iv. There have been 
conflicting reports on the efficacy of 10 mg metoclopramide in the prevention of postoperative 
nausea and vomiting. In a meta analysis by Henzi et al, it has been shown that this dose had no 
significant antinausea effect.69 This review by Henzi, et al involved 66 studies and 3260 patients 
who received 18 different regimens of metoclopramide and 3006 controls who received placebo 
or no treatment. There was no evidence of dose-responsiveness with oral, im, intranasal or iv 
metoclopramide in children and adults. The doses used in adults were 5-30 mg iv while 0.10-
0.50 mgkg-1 were used in children. The best documented regimen is 10 mg iv.69 
 High-dose metoclopramide has been used successfully as an antiemetic in highly emetogenic 
chemotherapy (treatment with Cisplatin, for instance).86 Metoclopramide in larger doses is said 
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to have anti-5-HT receptor action.87 Knudsen et al also found metoclopramide to be effective in 
counteracting emesis following spinal anaesthesia supplemented with intrathecal morphine.88 
This observation was confirmed by Pitkanem, and co-workers.89 
 Studies have also been done comparing the efficacy of metoclopramide plus other drugs 
combinations with other antiemetics. Eberhart et al compared dimenhydrinate (an antihistaminic) 
and metoclopramide alone and in combination for prophylaxis of PONV.90 Metoclopramide in a 
dose 0.3 mgkg-1 was used for the study. Neither metoclopramide nor dimenhydrinate alone 
reduced the incidence of PONV in male patients after endonasal surgery. However, the 
combination of both drugs revealed a moderate additive effect: PONV was reduced from 37.5% 
in the placebo group to 15.0%.90  
Yoshitaka et al studied the effects of 8 mg dexamethasone on antiemetics in female patients 
undergoing gynaecological surgery.91 The study demonstrated that incidence of complete 
response, no PONV, and no administration of rescue antiemetic medication was greater in 
patients who had received granisetron plus dexamethasone (96%) than in those who had received 
droperidol (49%) or metoclopramide plus dexamethasone (51%) (P = 0.001).91 
The doses of metoclopramide used in many previous studies are relatively low and optimum 
dose of metoclopramide used in combination with another antiemetic (e.g. dexamethasone) could 
be highly effective in the prophylaxis for postoperative nausea and vomiting. 
This hypothesis was put to test by Jan Wallenborn et al in their study.8 Jan Wallenborn et al 
investigated the efficacy and safety of three doses of metoclopramide (10 mg, 25 mg, and 50 
mg), on the assumption that each patient would receive basic antiemetic prophylaxis of 8 mg 
dexamethasone. They found that 25 mg or 50 mg metoclopramide added to the basic intervention 
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of 8 mg dexamethasone was effective, safe, and cheap.8 50 mg metoclopramide was however 
found to be more effective than 25 mg over 24 hours postoperatively. In their study the whole 50 
mg was given as a single dose intra-operatively but in the present study, metoclopramide was 
given in two divided doses of 25 mg each at the beginning and end of surgery respectively. 
Another meta-analysis reported that 10 mg metoclopramide was clinically ineffective and did not 
improve when combined with 8 mg dexamethasone.69 Larger dosages, however, were as 
effective as ondansetron or droperidol when added to dexamethasone (odds ratios around 0.5).7 
Metoclopramide is a relatively safe drug. Jan Wallenborn et al recorded low incidence of 
extrapyramidal symptoms while no incidence of extrapyramidal symptom was noted in this 
study.  This is probably due to larger sample size used in the previous study.8 It is also possible 
that giving the drug in two divided doses rather than as a bolus prevented the incidence of 
extrapyramidal effects in this study. 
Jan Wallenborn et al found that metoclopramide also reduced the number of multiple episodes of 
nausea and vomiting and the need for rescue drugs.8 Similarly in this study Metoclopramide 
reduced the number of multiple episodes of nausea (0% in Metoclopramide Group Vs 30.6% in 
the Control Group) and vomiting (0% in the Metoclopramide group Vs 2.8% in the Control 
Group) and the need for rescue drug (2.8% in the Metoclopramide Group Vs 13.9% in the 
Control Group) (Table 3). However, this was only statistically significant for multiple episodes 
of nausea (P = 0.003) and not statistically significant for multiple episodes of vomiting (P = 
0.218) and the need for rescue drug (P = 0.09). 
There have been conflicting reports on the efficacy of dexamethasone in the prevention of 
PONV. Several studies have found that dexamethasone is effective in prevention of PONV.13,92,93 
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In these studies, the antiemetic effect of dexamethasone was reported to be equal to or even 
better than that of serotonin subtype 3 (5-HT3) receptor antagonists such as ondansetron and 
granisetron.92, 93  Dexamethasone also reduced the occurrence of postoperative nausea and 
vomiting (PONV) in patients undergoing tonsillectomy, thyroidectomy, cholecystectomy and 
hysterectomy.13, 14, 28 However in another study, Jann-Inn Tzeng et al concluded that 
dexamethasone (8 mg) alone does not prevent PONV in women undergoing dilatation and 
curettage.27 Dexamethasone was however found to enhance the antiemetic effect of droperidol27. 
Although dexamethasone has been used in the prophylaxis of chemotherapy related emesis in a 
wide dose range (8 – 32 mg), 92, 93 a single fixed dose of 8 mg was most frequently used in the 
prevention against PONV.13, 14, 28This was the reason why a single fixed dose of dexamethasone 
of 8 mg was chosen in this study. 
Reviews dealing with PONV have discussed almost exclusively general anaesthesia and largely 
ignored regional anaesthesia. This contrasted with the increasing popularity of regional 
anaesthesia. A multitude of medications, such as synthetic opioids, α2-agonists, and 
cholinesterase inhibitors, have been introduced in an attempt to enhance the action of local 
anaesthetics. The decision about their usefulness will not only rely on their effects on nerve 
blockade and pain relief, but also on their influence on side effects such as PONV. 
Patients in this study had their surgery under spinal anaesthesia. Two patients whose anaesthesia 
was converted to general anaesthesia were excluded from the study. Regional anaesthesia has 
been reported to be less emetogenic than general anaesthesia.55-60 Intrathecal fentanyl was used 
for all patients in this study. It is possible that this could have further increased the risk of PONV 
in the patients that were studied.71 Intrathecal morphine is however more emetogenic than 
intrathecal fentanyl.5 
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Age 
Twenty-one patients (29.2%) had age ≥ 50years while fifty-one patients (70.8%) had age < 50 
years. In this study, age had no effects on the incidence of PONV (P = 0.66, Table 5). Jan 
Wallenborn et al noticed that early postoperative nausea and vomiting was less frequent in 
patients aged 50 or more but late episodes were more frequent, as were adverse reactions.8 There 
was no similar finding in this study. There was no difference in the incidence of PONV between 
patients aged 50 or more and patients aged less than 50 years throughout 24 hours (Table 5).  
Table 5. Incidence of PONV compared with Obesity and Age 
                                           PONV (n)                                       NO PONV (n) 
Age  
        P = 0.66 
        Age < 50 yr                   14                                                   37               
        Age ≥ 50 yr                    6                                                    15 
Obesity 
     P = 0.87 
     Obese (BMI ≥ 30)             3                                                    16 
     Not Obese (BMI < 30)      11                                                   42                               
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Soyannwo et al could not find significant relationship between age and PONV in their study.5 
Similarly, Berg Van den et al could not establish relationship between age and postoperative 
vomiting in their study.32 Cohen et al17 showed that the incidence of vomiting is no doubt higher 
in paediatric age groups when compared to adults. In a recent study, Alesandro CS et al also 
found PONV to be significantly associated with younger age (P = 0.034).94 All the patients in the 
present study were adults with age range of 21- 63 years unlike some previous studies that 
included patients with younger age range and larger population sample.94 Watcha and White 
concluded that the relationship between emesis and age is not as clear as relationship between 
gender and postoperative nausea and vomiting in adult population.12 
Obesity 
Body mass index (BMI) had no effects on postoperative nausea and vomiting in this study (P = 
0.87). Obesity has actually been disproved as a patient-related PONV risk factor .95 Interestingly, 
the systematic review that did so found that the belief in increased body mass index as a risk 
factor apparently largely stemmed from a “chain reaction” of 14 review articles misquoting or 
misinterpreting 4 original studies.95 
Postoperative pain 
Postoperative pain after gynaecological surgery may precipitate or aggravate PONV. Morphine, 
paracetamol and diclofenac were used for postoperative pain management in this study to 
minimise the influence of pain on PONV. In the Metoclopramide Group, 12 (33.3%) patients had 
pain in the first 24 hour while 24(66.7%) were free of pain (Table 6). On the other hand, 20 
(55.6%) patients in the Control Group had pain during the 24 hour period and 16 (44.4%) 
patients were free of pain. There was no statistically significant difference in the incidence of 
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pain between the two groups (P = 0.96). Therefore, pain could not have been responsible for the 
higher incidence of PONV noticed in the Control Group. 
Table 7 shows that among patients who experienced pain (mild, moderate and severe) and those 
who did not, there was no statistically significant difference in the incidence of PONV. In a 
similar vein, Stadler et al could not establish relationship between PONV and postoperative 
pain.96Some studies have however established postoperative pain as risk factor in PONV.12  
More patients in the Control Group (55.6%) had pain within 24 hours postoperatively compared 
with the Metoclopramide Group (33.3%)  (P = 0.96, Table 6). Although the difference was not 
statistically significant, the observed result may be due to the analgesic effect of metoclopramide 
that has been reported by some investigators.97,98 Ramaswamy et al found that metoclopramide 
produced a significant analgesic effect when tested by both acetic acid induced writhing and hot 
plate test.97 This effect was reduced by naloxone suggesting opioid involvement. Furthermore, 
bromocriptine which inhibits the release of prolactin attenuated the effect of metoclopramide 
indicating that this drug could act by releasing prolactin.97 Lisander agreed that metoclopramide 
may enhance analgesic effect of opioids and established that VAS-pain scores tended to be 
smaller in patients that had metoclopramide compared with those that had no metoclopramide. 
He however could not conclusively demonstrate clinically relevant analgesic effect of 
metoclopramide.98 
Type of surgery 
This study was conducted on patients undergoing major gynaecological surgery ranging from 
total abdominal hysterectomy to Manchester repair (Table 2). There was relative even 
distribution of types of surgery between the two study groups (P= 0.633). Some investigators 
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have established types of surgery as a risk factor in PONV.12 Whereas several other studies have 
suggested that differences in the incidence of PONV are mainly due to patient- or anesthesia-
specific factors, regardless of the type of surgery.99 However in a more recent study, Ruiz et al 
found that the type of surgery, when categorized anatomically, was associated with an increased 
frequency of early PACU antiemetic administration.100 
 Adverse events  
The adverse effects seen during the study are shown in Table 8.The most frequently reported side 
effects were dizziness and drowsiness which were relatively mild. No difference in the incidence 
of adverse effects was observed among the groups. Only one patient in the Metoclopramide 
Group had significant hypotension which responded to intravenous administration of ephedrine 3 
mg bolus and Normal Saline. No episode of extrapyramidal symptom was recorded throughout 
the study period. No patient complained of headache or vertigo in the both groups, although it 
might have been difficult to differentiate headache caused by spinal anaesthesia from that due to 
metoclopramide had there been an incidence in the Metoclopramide Group.  
Table 8. Adverse Effects 
                                     Metoclopramide Group (n)                     Control Group (n)                              
Any adverse effects                       11                                                  10                                
        Mild Hypotension                   8                                                    8 
        Moderate Hypotension         1                                                    0                                                                                                                                       
        Dizziness                                   1                                                    1                                       
        Drowsiness                               1                                                    1                                   
  n = 36 in each group. 
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  In a review of several randomized placebo-controlled studies by Henzi et al, they found no 
significant difference between metoclopramide and placebo for adverse drug reactions such as 
extrapyramidal symptoms, sedation and drowsiness, dizziness and vertigo, headaches.31Only one 
adult patient who had received 20 mg metoclopramide was found to have extrapyramidal 
symptom while no extrapyramidal symptom was found in children in their study. 
There was no episode of intraoperative vomiting in both groups during the present study. 
Conclusion and Recommendation 
Patients at high risk of PONV should receive special considerations with respect to the 
prophylactic use of antiemetic drugs. Due to different sites of action of antiemetic drugs, a 
combination therapy using two antiemetics (acting at different sites) together with less 
emetogenic anaesthetic procedure is more effective than monotherapy. A Combination of 8 mg 
dexamethasone and 50 mg metoclopramide in two divided doses given intravenously is effective 
in the prevention of PONV and it is strongly recommended for patients with high risk of 
developing PONV. It is found to be safe and cheap and this is in agreement with previous study. 
It is recommended that 25 mg metoclopramide be given after induction of anaesthesia and 25 mg 
at the closure of the skin. 
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